Skip to main content
Equibles
UPB logo

UPB · Upstream Bio, Inc. · Metrics

Track UPB — free

Use UPB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research UPB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.79 +0.04 (+1.45%) At close · Oct 27
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared May 13, 2026

The latest filing states the doubt was alleviated.

“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements. The Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these condensed consolidated financial statements.”
View the 10-Q filed May 13, 2026
Market Cap
$153.63M
Shares
54.77M
Volume · Oct 27 1.18M Avg daily vol (3M) 817.31K

UPB metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.79
Market cap
$153.63M

Price action

20 metrics
Price change (1W)
-1.8%
Price change (30D)
-48.1%
Price change (3M)
-57.0%
Price change (6M)
-70.4%
Price change (YTD)
-89.9%
Price change (1Y)
-87.4%
Trailing year
Price change (5Y)
—
52-week high
$32.60
52-week low
$2.74
Change from 52-week high
-91.6%
Change from 52-week low
+0.4%
Annualized volatility
89.9%
Annualized volatility (3M)
75.5%
Beta
1.2
RSI (14D)
20.4
Price vs SMA 50
-47.6%
Price vs SMA 200
-72.1%
Avg volume (3M)
806,230
Relative volume
1.2
Average dollar volume
$4.13M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
54.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-32.2×
EV / EBITDA
—
EV / EBIT
—
P / sales
50.6×
reciprocal yield 2.0%
P / book
0.6
reciprocal yield 169.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-98.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
125.1×
reciprocal yield 0.8%
EV / revenue historical average (5Y)
125.1×
reciprocal yield 0.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
-5,382.6%
Trailing 12 months
Net margin
-4,955.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$169.98M
Net income (TTM)
−$156.50M
Trailing 12 months
Diluted EPS (TTM)
$-2.89
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.13
EBITDA per diluted share (TTM)
$-3.13
Net income per diluted share (TTM)
$-2.89
Operating cash flow per diluted share (TTM)
$-2.51
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$2.69
Stock compensation per diluted share (TTM)
$0.26
Book value per share
$6.26

Growth

11 metrics
Revenue growth YoY
-17.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.16M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-57.8%
Return on assets
-55.7%
Debt / equity
0.0
Current ratio
28.0
EBITDA (TTM)
−$169.78M
Free cash flow (TTM)
—
Quick ratio
28.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$261.31M
Latest balance sheet
Cash & equivalents
$79.40M
Total assets
$281.17M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$136.34M
Capital expenditures (TTM)
$118,000
R&D (TTM)
$145.80M
SG&A (TTM)
—
Stock compensation (TTM)
$14.10M
R&D / revenue
4,616.8%
Stock compensation / revenue
446.5%

Ownership (13F)

9 metrics
13F filers
150
13F filer change QoQ
+7
Institutional ownership
92.4%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
33.1%
Private-fund adviser ownership
29.8%
Active holders' share change QoQ
+6.0%
Holder tenure
5.7
Price vs estimated holder cost
-61.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.4%

Short interest

3 metrics
Short interest
8.2%
Latest settlement · 3.7 days to cover
Days to cover
3.7d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$27,604
Insider-sentiment score
37 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2022626 CUSIP 91678A107 13F (30d) 12 filings 12 filers Visit website Investor relations